Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Apr 21, 2022

SELL
$8.69 - $12.48 $2,607 - $3,744
-300 Closed
0 $0
Q3 2020

Oct 27, 2020

SELL
$9.93 - $33.26 $3,703 - $12,405
-373 Reduced 55.42%
300 $4,000
Q2 2020

Aug 14, 2020

BUY
$2.9 - $10.71 $1,951 - $7,207
673 New
673 $7,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $426M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Atlas Private Wealth Advisors Portfolio

Follow Atlas Private Wealth Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atlas Private Wealth Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Atlas Private Wealth Advisors with notifications on news.